In a 2009 discussion on this board, you, microcapfun, and I wondered how much MAXY’s gene-shuffling technology was worth.
The answer, evidently, is not much—the effective price of today’s deal is even less than $20M because CDXS’ royalty obligations to MAXY have now been canceled.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.